One of the world’s leading figures in Artificial Intelligence, the renowned brain and cognitive scientist Newton Howard, PhD., will be at The Artificial Intelligence and Business Summit May 26 at the Intercontinental Dubai Festival City and will be available for interviews with Dubai and international media. The annual event for established professionals in the crypto and blockchain space brings together key brands and individuals from the converging sectors of AI, Blockchain, IoT, Quantum Tech to discuss and shape the future of emerging tech. Dr. Howard will also be traveling through the Gulf Region meeting with Heads of States, to discuss the application of Ai in their emerging economies.
“I’m delighted to be back in Dubai at this important event for the Artificial Intelligence community,” says Professor Howard, a professor of computational neuroscience and functional neurosurgery at the University of Oxford, and former founder and director of the MIT Mind Machine Project. “After years of research, we believe that A-I can provide the path to relief for millions of people suffering from Neurodegeneration such as Alzheimer’s, Parkinson’s and other neuro-brain disorders and mental diseases.”
At the Dubai conference Dr. Newton will be showcasing ni20, a dynamic spinout company from his Oxford team’s research, which is making life better for patients who suffer from debilitating brain diseases and disorders by restoring their abilities. Specifically, Dr. Howard and his team members from Oxford and MIT are developing a revolutionary brain-computer interface that addresses the most pressing and costly medical needs of a rapidly aging global population, the treatment of neurodegenerative brain diseases and disorders. “Our raison d’être is quite simple,” Dr. Howard says. “With neuron input to output, we strive to restore human dignity to patients who suffer with debilitating brain diseases and disorders by restoring their abilities.”
Ni2o was founded by a global team of experienced entrepreneurs, technologists and neuroscientists, research started at Oxford and then continued at MIT’s Mind Machine Project: Developing a revolutionary brain-computer interface that addresses the most pressing and costly medical needs of a rapidly aging global population, the treatment of neurodegenerative brain diseases and disorders. The global population of those aged 60 years or older (those most likely to face a neurodegenerative disease) will more than double by 2050. Dr. Howard’s new company ni2o is creating a breakthrough, minimally invasive, and technologically superior treatment while simultaneously driving down costs affording treatment to all those in need.
Dr. Howard’s plan is to begin by attacking the debilitating affliction of Parkinson’s Disease. Today, of the estimated 10 million people globally suffering with Parkinson’s, there are three proven deep brain stimulation (DBS) treatments on the market. However, they all require up to a 12-hour surgery, holes drilled into the skull, wires run through the neck to an implanted device in the chest, all coupled with potentially significant complications. Ni20’s minimally-invasive implant, KIWI, will change all of this. Kinetic Intelligent Wireless Implant (KIWI) is a small, self-contained, wirelessly connected, wirelessly charged, AI-driven replacement for current deep brain stimulation solutions.
KIWI will record brain activity and deliver electrical and optical signals to target areas, with algorithms that will determine the therapeutic response and be continually improved by machine learning. It is implanted using an internally-developed, minimally-invasive surgical procedure. A cloud-based software platform will then securely collect and interpret information in real-time. Existing DBS devices are primitive and excessively invasive, requiring a lengthy procedure ending in permanent trepanation. No larger than a grain of rice, KIWI is embedded via a minimally-invasive operation into areas of the brain where clinical treatment is required. Neurons readily grow around the device’s carbon nanotube connectors, which deliver the small electrical pulses that are the basis of the effectiveness of DBS.
Once ni2o conquers Parkinson’s disease, Dr. Howard and his team of scientists and research physicians will turn their focus to Alzheimer’s disease. “The technology is revolutionary, the plan is bold, and we believe the outcomes will benefit mankind for generations to come,” Dr. Howard adds. “We believe the world will be faced with unsustainable costs and burdens on society to adequately care for the growing and aging population with the dignity they deserve.”